United States Biotechnology & Medical Research

Prelude Therapeutics Inc (PRLD)

Track

Over the past 90 days, Prelude Therapeutics Inc. recorded significant insider activity, with two insiders executing four buy transactions totaling approximately $25 million. These purchases represent a net increase in insider holdings. This activity follows the company's recent earnings report, which showed a positive earnings surprise, and occurs amid a 9.2% increase in stock price.
Ticker: PRLD Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Prelude Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Bonita David P
2 purchases — total 12,499,999 USD
Buy 21 Apr 2026
Value US$3,508,653.54 | Price 357.19 | Shares 61,812
Buy 21 Apr 2026
Value US$4,129,813.91 | Price 166.86 | Shares 58,143
Buy 21 Apr 2026
Value US$861,093.70 | Price 401.12 | Shares 97,280
Buy 21 Apr 2026
Value US$955,170.82 | Price 280.09 | Shares 51,912
Planned buy 25 Mar 2025
Value US$69,250.00 | Price 0.69 | Shares 100,000
Buy 25 Mar 2025
Value US$467,437.50 | Price 0.69 | Shares 675,000
Buy 21 Mar 2025
Value US$10,959.00 | Price 0.73 | Shares 15,000
Buy 20 Mar 2025
Value US$3,950.43 | Price 0.73 | Shares 5,416
Buy 17 Mar 2025
Value US$6,828.59 | Price 0.75 | Shares 9,106
Buy 14 Mar 2025
Value US$22,631.25 | Price 0.75 | Shares 29,999
Buy 13 Mar 2025
Value US$35,820.00 | Price 0.72 | Shares 50,000
Buy 12 Mar 2025
Value US$33,744.00 | Price 0.71 | Shares 47,500
Buy 31 Dec 2024
Value US$6,043.50 | Price 1.21 | Shares 5,000
Buy 30 Dec 2024
Value US$12,000.00 | Price 1.20 | Shares 10,000
Buy 23 Dec 2024
Value US$82,002.00 | Price 1.37 | Shares 60,000
Planned buy 20 Dec 2024
Value US$3,536.25 | Price 1.15 | Shares 3,075
Buy 19 Dec 2024
Value US$22,637.50 | Price 0.91 | Shares 25,000
Buy 19 Dec 2024
Value US$6,115.86 | Price 0.89 | Shares 6,888
Buy 18 Dec 2024
Value US$93,210.00 | Price 0.93 | Shares 100,000
Buy 25 May 2023
Value US$4,779.00 | Price 5.31 | Shares 900
Buy 24 May 2023
Value US$5,011.40 | Price 5.01 | Shares 1,000
Buy 24 May 2023
Value US$12,936.00 | Price 5.39 | Shares 2,400
Buy 23 May 2023
Value US$66,749.28 | Price 5.63 | Shares 11,856
Planned buy 23 May 2023
Value US$27,500.00 | Price 5.50 | Shares 5,000
Buy 22 May 2023
Value US$4,999,998.75 | Price 5.75 | Shares 869,565
Buy 22 May 2023
Value US$4,999,998.75 | Price 5.75 | Shares 869,565
Sale 6 Apr 2023
Value US$81,273.60 | Price 6.12 | Shares 13,280
Buy 20 Dec 2022
Value US$98,445.95 | Price 5.13 | Shares 19,188
Planned buy 8 Dec 2022
Value US$47,600.00 | Price 4.76 | Shares 10,000
Buy 1 Jun 2022
Value US$42,300.00 | Price 4.23 | Shares 10,000
Planned sale 15 Dec 2021
Value US$373,763.00 | Price 13.00 | Shares 28,751
Buy 14 Dec 2021
Value US$46,400.00 | Price 11.60 | Shares 4,000
Buy 13 Dec 2021
Value US$48,480.00 | Price 12.12 | Shares 4,000
Planned sale 16 Nov 2021
Value US$6,570.00 | Price 16.43 | Shares 400
Planned sale 16 Nov 2021
Value US$449,961.56 | Price 15.87 | Shares 28,351
Planned sale 5 Oct 2021
Value US$41,330.11 | Price 32.06 | Shares 1,289
Planned sale 5 Oct 2021
Value US$244,257.31 | Price 31.30 | Shares 7,803
Planned sale 5 Oct 2021
Value US$178,762.49 | Price 30.26 | Shares 5,908
Planned sale 7 Jun 2021
Value US$415,664.65 | Price 32.73 | Shares 12,700
Planned sale 7 Jun 2021
Value US$28,461.96 | Price 31.62 | Shares 900
Planned sale 7 Jun 2021
Value US$42,495.74 | Price 30.35 | Shares 1,400
Planned sale 25 May 2021
Value US$14,401.11 | Price 36.09 | Shares 399
Planned sale 25 May 2021
Value US$61,535.82 | Price 35.45 | Shares 1,736
Planned sale 25 May 2021
Value US$105,337.55 | Price 34.11 | Shares 3,088
Planned sale 25 May 2021
Value US$104,262.75 | Price 33.53 | Shares 3,110
Planned sale 7 May 2021
Value US$8,370.00 | Price 41.85 | Shares 200
Planned sale 7 May 2021
Value US$240,090.12 | Price 41.14 | Shares 5,836
Planned sale 7 May 2021
Value US$159,732.15 | Price 40.30 | Shares 3,964
Planned sale 5 May 2021
Value US$45,544.63 | Price 41.07 | Shares 1,109
Planned sale 5 May 2021
Value US$422,148.23 | Price 40.30 | Shares 10,476
Planned sale 5 May 2021
Value US$134,399.03 | Price 39.36 | Shares 3,415
Planned sale 29 Apr 2021
Value US$132,764.78 | Price 40.29 | Shares 3,295
Planned sale 29 Apr 2021
Value US$129,853.38 | Price 40.29 | Shares 3,223
Planned sale 27 Apr 2021
Value US$61,790.54 | Price 36.11 | Shares 1,711
Planned sale 27 Apr 2021
Value US$556,579.72 | Price 35.68 | Shares 15,601
Planned sale 27 Apr 2021
Value US$266,477.61 | Price 34.66 | Shares 7,688
Planned sale 19 Apr 2021
Value US$125,076.80 | Price 31.27 | Shares 4,000
Planned sale 19 Apr 2021
Value US$647,272.50 | Price 30.82 | Shares 21,000
Planned sale 8 Apr 2021
Value US$8,000.00 | Price 40.00 | Shares 200
Planned sale 8 Apr 2021
Value US$66,040.33 | Price 39.57 | Shares 1,669
Planned sale 8 Apr 2021
Value US$26,072.67 | Price 38.97 | Shares 669
Planned sale 8 Apr 2021
Value US$33,003.42 | Price 37.72 | Shares 875
Planned sale 8 Apr 2021
Value US$52,387.48 | Price 36.97 | Shares 1,417
Planned sale 7 Apr 2021
Value US$8,060.00 | Price 40.30 | Shares 200
Planned sale 7 Apr 2021
Value US$272,678.89 | Price 39.63 | Shares 6,881
Planned sale 7 Apr 2021
Value US$323,405.28 | Price 39.02 | Shares 8,289
Planned sale 7 Apr 2021
Value US$281,115.77 | Price 39.69 | Shares 7,083
Planned sale 7 Apr 2021
Value US$323,907.50 | Price 39.03 | Shares 8,300
Buy 29 Sep 2020
Value US$19,000.00 | Price 19.00 | Shares 1,000
Buy 29 Sep 2020
Value US$8,436.00 | Price 19.00 | Shares 444
Buy 29 Sep 2020
Value US$190,000.00 | Price 19.00 | Shares 10,000
Buy 29 Sep 2020
Value US$71,250.00 | Price 19.00 | Shares 3,750
Buy 25 Sep 2020
Value US$13,499,500.00 | Price 19.00 | Shares 710,500
Buy 25 Sep 2020
Value US$9,999,700.00 | Price 19.00 | Shares 526,300
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-23 2026-04-21 B Purchase
3.0
Bonita David P
Non-Executive Director Large shareholder
61,812 -48.2%
357.19
US$3,508,654 		61,812 -48.2% 357.19 US$3,508,654
2026-04-23 2026-04-21 B Purchase
3.0
Bonita David P
Non-Executive Director Large shareholder
58,143 +42.1%
166.86
US$4,129,814 		58,143 +42.1% 166.86 US$4,129,814
2026-04-23 2026-04-21 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
97,280 -6.0%
401.12
US$861,094 		97,280 -6.0% 401.12 US$861,094
2026-04-23 2026-04-21 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
1,689,189 +16.7%
4.44
US$7,499,999 		1,689,189 +16.7% 4.44 US$7,499,999
2025-03-27 2025-03-25 PP Planned purchase
1.2
Combs Andrew

Chief Chemistry Officer

Officer
100,000 +26.3%
0.69
US$69,250 		100,000 +26.3% 0.69 US$69,250
2025-03-27 2025-03-25 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
675,000 +51.0%
0.69
US$467,438 		675,000 +51.0% 0.69 US$467,438
2025-03-24 2025-03-21 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
15,000 +1.1%
0.73
US$10,959 		15,000 +1.1% 0.73 US$10,959
2025-03-24 2025-03-20 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
5,416 +0.4%
0.73
US$3,950 		5,416 +0.4% 0.73 US$3,950
2025-03-18 2025-03-17 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
9,106 +0.7%
0.75
US$6,829 		9,106 +0.7% 0.75 US$6,829
2025-03-18 2025-03-14 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
29,999 +2.4%
0.75
US$22,631 		29,999 +2.4% 0.75 US$22,631
2025-03-14 2025-03-13 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
50,000 +4.1%
0.72
US$35,820 		50,000 +4.1% 0.72 US$35,820
2025-03-14 2025-03-12 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
47,500 +4.1%
0.71
US$33,744 		47,500 +4.1% 0.71 US$33,744
2025-01-03 2024-12-31 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
5,000 +3.6%
1.21
US$6,044 		5,000 +3.6% 1.21 US$6,044
2025-01-02 2024-12-30 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
10,000 +7.8%
1.20
US$12,000 		10,000 +7.8% 1.20 US$12,000
2024-12-26 2024-12-23 B Purchase
1.2
Combs Andrew

Chief Chemistry Officer

Officer
60,000 +18.9%
1.37
US$82,002 		60,000 +18.9% 1.37 US$82,002
2024-12-26 2024-12-20 PP Planned purchase
1.2
Combs Andrew

Chief Chemistry Officer

Officer
3,075 +1.0%
1.15
US$3,536 		3,075 +1.0% 1.15 US$3,536
2024-12-20 2024-12-19 B Purchase
1.9
Lim Bryant David

CLO, Interim CFO, Corp Sec.

Officer
25,000 +1041.7%
0.91
US$22,638 		25,000 +1041.7% 0.91 US$22,638
2024-12-20 2024-12-19 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
6,888 +5.7%
0.89
US$6,116 		6,888 +5.7% 0.89 US$6,116
2024-12-20 2024-12-18 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
100,000 +9.4%
0.93
US$93,210 		100,000 +9.4% 0.93 US$93,210
2023-05-26 2023-05-25 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
900 +0.1%
5.31
US$4,779 		900 +0.1% 5.31 US$4,779
2023-05-26 2023-05-24 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
1,000 +0.1%
5.01
US$5,011 		1,000 +0.1% 5.01 US$5,011
2023-05-25 2023-05-24 B Purchase
1.9
Lim Bryant David

Chief Legal Officer, Corp Sec.

Officer
2,400 +inf%
5.39
US$12,936 		2,400 +inf% 5.39 US$12,936
2023-05-25 2023-05-23 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
11,856 +1.1%
5.63
US$66,749 		11,856 +1.1% 5.63 US$66,749
2023-05-25 2023-05-23 PP Planned purchase
3.6
Chardonnet Laurent

Chief Financial Officer

Officer
5,000 +13.5%
5.50
US$27,500 		5,000 +13.5% 5.50 US$27,500
2023-05-24 2023-05-22 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
869,565 +9.4%
5.75
US$4,999,999 		869,565 +9.4% 5.75 US$4,999,999
2023-05-24 2023-05-22 B Purchase
3.0
Bonita David P
Non-Executive Director Large shareholder
869,565 +9.4%
5.75
US$4,999,999 		869,565 +9.4% 5.75 US$4,999,999
2023-04-06 2023-04-06 S Sale
2.5
Huang Jane

President, CMO

Officer
13,280 -35.4%
6.12
US$81,274 		13,280 -35.4% 6.12 US$81,274
2022-12-21 2022-12-20 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
19,188 +18.9%
5.13
US$98,446 		19,188 +18.9% 5.13 US$98,446
2022-12-12 2022-12-08 PP Planned purchase
3.6
Chardonnet Laurent

Chief Financial Officer

Officer
10,000 +38.7%
4.76
US$47,600 		10,000 +38.7% 4.76 US$47,600
2022-06-01 2022-06-01 B Purchase
3.6
Chardonnet Laurent

Chief Financial Officer

Officer
10,000 +69.0%
4.23
US$42,300 		10,000 +69.0% 4.23 US$42,300
2021-12-17 2021-12-15 PlS Planned sale
Morosini Deborah

EVP, Chief of Clinical Affairs

Officer
28,751 -98.5%
13.00
US$373,763 		28,751 -98.5% 13.00 US$373,763
2021-12-15 2021-12-14 B Purchase
1.2
Combs Andrew

EVP, Head of Chemistry

Officer
4,000 +1.5%
11.60
US$46,400 		4,000 +1.5% 11.60 US$46,400
2021-12-15 2021-12-13 B Purchase
1.2
Combs Andrew

EVP, Head of Chemistry

Officer
4,000 +1.5%
12.12
US$48,480 		4,000 +1.5% 12.12 US$48,480
2021-11-18 2021-11-16 PlS Planned sale
Morosini Deborah

EVP, Chief of Clinical Affairs

Officer
400 -47.4%
16.43
US$6,570 		400 -47.4% 16.43 US$6,570
2021-11-18 2021-11-16 PlS Planned sale
Morosini Deborah

EVP, Chief of Clinical Affairs

Officer
28,351 -97.1%
15.87
US$449,962 		28,351 -97.1% 15.87 US$449,962
2021-10-06 2021-10-05 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
1,289 -100.0%
32.06
US$41,330 		1,289 -100.0% 32.06 US$41,330
2021-10-06 2021-10-05 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
7,803 -85.8%
31.30
US$244,257 		7,803 -85.8% 31.30 US$244,257
2021-10-06 2021-10-05 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
5,908 -39.4%
30.26
US$178,762 		5,908 -39.4% 30.26 US$178,762
2021-06-09 2021-06-07 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
12,700 -100.0%
32.73
US$415,665 		12,700 -100.0% 32.73 US$415,665
2021-06-09 2021-06-07 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
900 -6.6%
31.62
US$28,462 		900 -6.6% 31.62 US$28,462
2021-06-09 2021-06-07 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
1,400 -9.3%
30.35
US$42,496 		1,400 -9.3% 30.35 US$42,496
2021-05-27 2021-05-25 PlS Planned sale
Piper Brian

Chief Financial Officer

Officer
399 -100.0%
36.09
US$14,401 		399 -100.0% 36.09 US$14,401
2021-05-27 2021-05-25 PlS Planned sale
Piper Brian

Chief Financial Officer

Officer
1,736 -81.3%
35.45
US$61,536 		1,736 -81.3% 35.45 US$61,536
2021-05-27 2021-05-25 PlS Planned sale
Piper Brian

Chief Financial Officer

Officer
3,088 -59.1%
34.11
US$105,338 		3,088 -59.1% 34.11 US$105,338
2021-05-27 2021-05-25 PlS Planned sale
Piper Brian

Chief Financial Officer

Officer
3,110 -37.3%
33.53
US$104,263 		3,110 -37.3% 33.53 US$104,263
2021-05-11 2021-05-07 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
200 -0.1%
41.85
US$8,370 		200 -0.1% 41.85 US$8,370
2021-05-11 2021-05-07 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
5,836 -3.3%
41.14
US$240,090 		5,836 -3.3% 41.14 US$240,090
2021-05-11 2021-05-07 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
3,964 -2.2%
40.30
US$159,732 		3,964 -2.2% 40.30 US$159,732
2021-05-10 2021-05-05 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
1,109 -100.0%
41.07
US$45,545 		1,109 -100.0% 41.07 US$45,545
2021-05-10 2021-05-05 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
10,476 -90.4%
40.30
US$422,148 		10,476 -90.4% 40.30 US$422,148
2021-05-10 2021-05-05 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
3,415 -22.8%
39.36
US$134,399 		3,415 -22.8% 39.36 US$134,399
2021-04-30 2021-04-29 PlS Planned sale
Pierce Christopher

EVP and Chief of Business Oper

Officer
3,295 -46.8%
40.29
US$132,765 		3,295 -46.8% 40.29 US$132,765
2021-04-30 2021-04-29 PlS Planned sale
Morosini Deborah

EVP, Chief of Clinical Affairs

Officer
3,223 -87.9%
40.29
US$129,853 		3,223 -87.9% 40.29 US$129,853
2021-04-29 2021-04-27 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
1,711 -100.0%
36.11
US$61,791 		1,711 -100.0% 36.11 US$61,791
2021-04-29 2021-04-27 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
15,601 -90.1%
35.68
US$556,580 		15,601 -90.1% 35.68 US$556,580
2021-04-29 2021-04-27 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
7,688 -30.8%
34.66
US$266,478 		7,688 -30.8% 34.66 US$266,478
2021-04-21 2021-04-19 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
4,000 -100.0%
31.27
US$125,077 		4,000 -100.0% 31.27 US$125,077
2021-04-21 2021-04-19 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
21,000 -84.0%
30.82
US$647,272 		21,000 -84.0% 30.82 US$647,272
2021-04-15 2021-04-08 PlS Planned sale
Pierce Christopher

EVP and Chief of Business Oper

Officer
200 -5.1%
40.00
US$8,000 		200 -5.1% 40.00 US$8,000
2021-04-15 2021-04-08 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
1,669 -1.0%
39.57
US$66,040 		1,669 -1.0% 39.57 US$66,040
2021-04-15 2021-04-08 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
669 -0.4%
38.97
US$26,073 		669 -0.4% 38.97 US$26,073
2021-04-15 2021-04-08 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
875 -0.5%
37.72
US$33,003 		875 -0.5% 37.72 US$33,003
2021-04-15 2021-04-08 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
1,417 -0.8%
36.97
US$52,387 		1,417 -0.8% 36.97 US$52,387
2021-04-09 2021-04-07 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
200 -0.1%
40.30
US$8,060 		200 -0.1% 40.30 US$8,060
2021-04-09 2021-04-07 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
6,881 -3.8%
39.63
US$272,679 		6,881 -3.8% 39.63 US$272,679
2021-04-09 2021-04-07 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
8,289 -4.4%
39.02
US$323,405 		8,289 -4.4% 39.02 US$323,405
2021-04-09 2021-04-07 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
7,083 -100.0%
39.69
US$281,116 		7,083 -100.0% 39.69 US$281,116
2021-04-09 2021-04-07 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
8,300 -54.0%
39.03
US$323,908 		8,300 -54.0% 39.03 US$323,908
2020-09-29 2020-09-29 B Purchase
1.2
Combs Andrew

EVP, Head of Chemistry

Officer
1,000 +0.4%
19.00
US$19,000 		1,000 +0.4% 19.00 US$19,000
2020-09-29 2020-09-29 B Purchase
Morosini Deborah

EVP, Chief of Clinical Affairs

Officer
444 +inf%
19.00
US$8,436 		444 +inf% 19.00 US$8,436
2020-09-29 2020-09-29 B Purchase
2.4
Dier Mardi
Non-Executive Director
10,000 +inf%
19.00
US$190,000 		10,000 +inf% 19.00 US$190,000
2020-09-29 2020-09-29 B Purchase
Pierce Christopher

EVP and Chief of Business Oper

Officer
3,750 +inf%
19.00
US$71,250 		3,750 +inf% 19.00 US$71,250
2020-09-29 2020-09-25 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
710,500 +343.4%
19.00
US$13,499,500 		710,500 +343.4% 19.00 US$13,499,500
2020-09-29 2020-09-25 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
526,300 +inf%
19.00
US$9,999,700 		526,300 +inf% 19.00 US$9,999,700
Explore more

More insider trading research around Prelude Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America